MedTrace Logo

Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)

NCT05967143 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 845

Last updated 2024-11-27

No results posted yet for this study

Summary

This registry seeks to prospectively gather a large repository of comprehensive observational data reflecting routine use of SIR-Spheres in patients diagnosed with unresectable HCC or unresectable liver metastases from mCRC refractory to or intolerant to chemotherapy, in order to assess clinical response in a real-world setting and further validate the safe and appropriate use of SIR-Spheres

Conditions

  • Unresectable Hepatocellular Carcinoma (HCC)
  • Liver Metastases From Colorectal Cancer (mCRC)

Interventions

DEVICE

SIRT

Selective internal radiation therapy with SIR-Spheres Y90 resin microspheres.

Sponsors & Collaborators

  • Sirtex Medical

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-19
Primary Completion
2028-06-30
Completion
2029-06-30
FDA Device
Yes

Countries

  • France
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05967143 on ClinicalTrials.gov